FLAME
2016
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
In 3,362 COPD patients with ≥1 exacerbation in the prior year, indacaterol-glycopyrronium (LABA/LAMA) reduced annual exacerbation rate compared with salmeterol-fluticasone (LABA/ICS).
Result
Efficacy: Annual rate of all COPD exacerbationsRate ratio 0.89 (95% CI 0.83-0.96) · P = 0.003
Below 1 favours indacaterol-glycopyrronium (LABA/LAMA), above 1 favours salmeterol-fluticasone (LABA/ICS).
Also reported: Moderate-or-severe RR 0.83. Pneumonia 3.2% vs 4.8%.
- Subtopic
- LABA/LAMA vs ICS/LABA
- Design
- RCT
- Relevance
- Important: one of several pillars.
- Source
- Wedzicha JA, et al. N Engl J Med. 2016;374(23):2222-2234.doi 10.1056/NEJMoa1516385
Discussion & critique
Reshaped GOLD recommendations toward dual bronchodilator first-line for non-eosinophilic exacerbators.